ULTRAGENYX PHARMACEUTICAL INC
Reported by Columbia Wanger Asset Management LLC
Reported 863,392 shares, down 97,753 (10.2%) from the prior quarter.
Reported value -30.6%; share count -10.2% vs. the prior quarter.
Reported position value by quarter
Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.
| Date | Holding Value |
|---|---|
| 2014-03-31 | 81868000 |
| 2014-06-30 | 77393000 |
| 2014-09-30 | 101375000 |
| 2014-12-31 | 58386000 |
| 2015-03-31 | 139374000 |
| 2015-06-30 | 238996000 |
| 2015-09-30 | 120639000 |
| 2015-12-31 | 124695000 |
| 2016-03-31 | 60850000 |
| 2016-06-30 | 42229000 |
| 2016-09-30 | 89191000 |
| 2016-12-31 | 82658000 |
| 2017-03-31 | 83900000 |
| 2017-06-30 | 84745000 |
| 2017-09-30 | 85021000 |
| 2017-12-31 | 67000000 |
Quarterly position history
How this manager's reported quarter-end position changed over time.
| Quarter | Activity | Shares | Change | % of reported 13F | Reported value | Filed | Source filing |
|---|---|---|---|---|---|---|---|
| Q4 2017 | Reduced | 1,444,584 | -151,750 (-9.5%) | 1.0% | $67,000,000 | 2018-02-13 | |
| Q3 2017 | Added | 1,596,334 | +231,900 (17.0%) | 1.26% | $85,021,000 | 2017-11-13 | |
| Q2 2017 | Added | 1,364,434 | +126,609 (10.2%) | 1.21% | $84,745,000 | 2017-08-11 | |
| Q1 2017 | Added | 1,237,825 | +62,209 (5.3%) | 1.18% | $83,900,000 | 2017-05-12 | |
| Q4 2016 | Reduced | 1,175,616 | -81,655 (-6.5%) | 1.16% | $82,658,000 | 2017-02-10 | |
| Q3 2016 | Added | 1,257,271 | +393,879 (45.6%) | 1.17% | $89,191,000 | 2016-11-10 | |
| Q2 2016 | Reduced | 863,392 | -97,753 (-10.2%) | 0.49% | $42,229,000 | 2016-08-12 | |
| Q1 2016 | Reduced | 961,145 | -150,421 (-13.5%) | 0.66% | $60,850,000 | 2016-05-12 | |
| Q4 2015 | Reduced | 1,111,566 | -141,048 (-11.3%) | 1.25% | $124,695,000 | 2016-02-08 | |
| Q3 2015 | Reduced | 1,252,614 | -1,081,559 (-46.3%) | 0.96% | $120,639,000 | 2015-11-10 | |
| Q2 2015 | Added | 2,334,173 | +89,463 (4.0%) | 1.54% | $238,996,000 | 2015-08-13 | |
| Q1 2015 | Added | 2,244,710 | +914,143 (68.7%) | 0.76% | $139,374,000 | 2015-05-01 | |
| Q4 2014 | Reduced | 1,330,567 | -460,515 (-25.7%) | 0.29% | $58,386,000 | 2015-02-06 | |
| Q3 2014 | Reduced | 1,791,082 | -2,100 (-0.1%) | 0.47% | $101,375,000 | 2014-11-12 | |
| Q2 2014 | Reduced | 1,793,182 | -2,300 (-0.1%) | 0.31% | $77,393,000 | 2014-08-12 | |
| Q1 2014 | New | 1,795,482 | +1,795,482 (0.0%) | 0.32% | $81,868,000 | 2014-05-12 |
Who else reported the position
162 managers reported ULTRAGENYX PHARMACEUTICAL INC for Q2 2016.
| Manager | Activity | Shares | Change | % of reported 13F | Reported value | Tenure |
|---|---|---|---|---|---|---|
| FMR LLC | Added | 5,847,783 | +6,152 | 0.04% | $286,015,000 | 10 qtrs |
| Capital Research Global Investors | Added | 4,778,169 | +11,696 | 0.08% | $233,700,000 | 10 qtrs |
| WELLINGTON MANAGEMENT GROUP LLP | Added | 4,188,184 | +55,754 | 0.05% | $204,844,000 | 10 qtrs |
| VANGUARD GROUP INC | Added | 2,589,718 | +120,999 | < 0.01% | $126,664,000 | 10 qtrs |
| PRICE T ROWE ASSOCIATES INC MD | Added | 1,591,977 | +242,340 | 0.02% | $77,864,000 | 10 qtrs |
| BlackRock Fund Advisors | Reduced | 1,390,985 | -51,866 | 0.02% | $68,033,000 | 10 qtrs |
| WELLS FARGO & COMPANY MN | Reduced | 1,348,155 | -380,807 | 0.03% | $65,939,000 | 10 qtrs |
| STATE STREET CORPORATION | Reduced | 1,268,686 | -15,638 | < 0.01% | $62,048,000 | 10 qtrs |
| BlackRock Institutional Trust Company N A | Reduced | 879,001 | -12,939 | < 0.01% | $42,992,000 | 10 qtrs |
| Columbia Wanger Asset Management LLC This report | Reduced | 863,392 | -97,753 | 0.49% | $42,229,000 | 10 qtrs |
Filing details and methodology As reported
- Report period
- June 30, 2016
- Filed
- August 12, 2016
- Filing type
- 13F-HR
- Position type
- COM
Voting authority reported
- Sole
- 767,888
- Shared
- 0
- None
- 95,504
“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.
Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.